Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients
NCT02732457 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 5
Last updated 2021-11-08
Summary
The purpose of this study is to assess the impact of allogeneic hematopoietic stem cell transplantations (HSCT) in HIV infected patients on the persistence of HIV and the HIV immune response.
Conditions
- HIV-1 Infection
Sponsors & Collaborators
-
Kirby Institute
lead OTHER_GOV
Principal Investigators
-
Mark Polizzotto, MD · St Vincent's Hospital, Sydney
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-09-30
- Primary Completion
- 2015-02-28
- Completion
- 2015-02-28
Countries
- Australia
Study Locations
More Related Trials
-
Age-related Clonal Haematopoiesis in an HIV Evaluation Cohort (ARCHIVE)
NCT04641013 ·Status: ACTIVE_NOT_RECRUITING
-
An Extension of Protocol PRO 140_CD01 Study
NCT02355184 ·Status: TERMINATED ·Phase: PHASE2
-
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
NCT01814722 ·Status: TERMINATED
-
The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection
NCT00641641 ·Status: COMPLETED ·Phase: NA
-
Addition of Raltegravir to Established Antiretroviral Suppressive Therapy
NCT01245101 ·Status: TERMINATED ·Phase: PHASE4
-
The Use of Leukapheresis to Support HIV Pathogenesis Studies
NCT01161199 ·Status: RECRUITING
-
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease
NCT00775606 ·Status: TERMINATED ·Phase: PHASE4
-
Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy
NCT02471430 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of the Effectiveness of Passive Immunotherapy in HIV-Infected Patients Who Are in Virologic Failure
NCT00353327 ·Status: SUSPENDED ·Phase: PHASE2/PHASE3
-
Raltegravir as Early Therapy in African-Americans Living With HIV Study
NCT00667433 ·Status: COMPLETED ·Phase: PHASE1
-
Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV
NCT05215704 ·Status: RECRUITING
-
Viral and Host Factors in the Transmission and Pathogenesis of HIV
NCT00219947 ·Status: TERMINATED
-
Effectiveness of Antiretroviral Therapy During Acute HIV Infection
NCT00705926 ·Status: COMPLETED ·Phase: PHASE1
-
Pausing Antiretroviral Treatment Under Structured Evaluation
NCT06031272 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
NCT01270802 ·Status: COMPLETED ·Phase: PHASE4
-
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
NCT01266902 ·Status: COMPLETED ·Phase: PHASE3
-
Transplantation and the Use of Raltegravir in HIV-Infected Patients
NCT01793467 ·Status: COMPLETED
-
Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria
NCT01044771 ·Status: COMPLETED ·Phase: NA
-
PRO 140 for Human Immunodeficiency Virus Infection
NCT02257788 ·Status: WITHDRAWN ·Phase: PHASE2
-
Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens
NCT00627055 ·Status: COMPLETED ·Phase: PHASE4
-
Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV
NCT04249037 ·Status: TERMINATED ·Phase: PHASE4
-
Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral Therapy
NCT00001899 ·Status: COMPLETED
-
Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load
NCT01620736 ·Status: WITHDRAWN ·Phase: PHASE2
-
Sequential HIV Therapy in Treatment Resistant HIV-1 Infected Patients
NCT00128908 ·Status: TERMINATED ·Phase: PHASE4
-
Raltegravir Intensification in HIV-infected Patients
NCT00631449 ·Status: COMPLETED ·Phase: PHASE4